About Dr. Jiang Lindi
Dr. Jiang Lindi (姜林娣) is one of China's most distinguished rheumatologists and the Director of the Department of Rheumatology and Immunology at Zhongshan Hospital, affiliated with Fudan University. She holds the title of Chief Physician and Professor and is nationally recognized as a leading authority on systemic lupus erythematosus, vasculitis, and inflammatory arthritis.
Over a career spanning more than three decades, Dr. Jiang has established Zhongshan Hospital's Rheumatology Department as one of the premier autoimmune disease centers in Shanghai. She is particularly renowned for her expertise in ANCA-associated vasculitis, lupus nephritis, and biologic therapy for inflammatory arthritis — areas where her contributions have shaped national clinical guidelines and influenced rheumatology practice across China.
International patients with autoimmune conditions — including SLE, vasculitis, rheumatoid arthritis, and inflammatory myopathies — consistently identify Dr. Jiang as one of Shanghai's top rheumatologists for both primary treatment and expert second opinions.
Professional Positions and Affiliations
- Director, Department of Rheumatology and Immunology, Zhongshan Hospital, Fudan University
- Chairwoman, Vasculitis Committee, Chinese Rheumatology Association
- Vice Chairwoman, Chinese Rheumatology Association
- Editorial Board Member: Annals of the Rheumatic Diseases, Rheumatology, Clinical Rheumatology
- Member, European League Against Rheumatism (EULAR)
- Member, American College of Rheumatology (ACR)
- Member, European Vasculitis Society (EUVAS)
Specialties and Clinical Expertise
- ANCA-Associated Vasculitis — granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA); rituximab and cyclophosphamide induction; avacopan for complement-mediated vasculitis; maintenance therapy and relapse management
- Systemic Lupus Erythematosus (SLE) — lupus nephritis, neuropsychiatric lupus, and hematologic lupus; biologic therapy (belimumab, anifrolumab); immunosuppressive protocols; pregnancy in lupus management
- Rheumatoid Arthritis (RA) — treat-to-target protocols; biologic therapy (TNF inhibitors, IL-6 inhibitors, abatacept); JAK inhibitors (upadacitinib, baricitinib, filgotinib); remission maintenance
- Inflammatory Myopathies — dermatomyositis, polymyositis, and anti-synthetase syndrome; interstitial lung disease (ILD) management; rituximab for refractory cases
- Sjogren's Syndrome — systemic manifestations, sicca symptom management, and lymphoma surveillance
- Systemic Sclerosis — skin, pulmonary, renal, and vascular complications; nintedanib and tocilizumab for ILD
- Crystal Arthropathy — gout and pseudogout; urate-lowering therapy optimization; pegloticase for refractory gout
- Antiphospholipid Syndrome (APS) — thrombotic and obstetric APS; anticoagulation management and pregnancy planning
Academic and Research Contributions
Dr. Jiang Lindi has published over 160 peer-reviewed papers in leading international rheumatology journals, with a particular focus on ANCA-associated vasculitis in Chinese patients, lupus nephritis outcomes, and the optimization of biologic therapy in inflammatory arthritis. Her landmark research on the clinical features and outcomes of ANCA-associated vasculitis in Chinese patients — one of the largest cohort studies in Asia — has been widely cited and has contributed to international understanding of vasculitis in Asian populations.
She chairs the Vasculitis Committee of the Chinese Rheumatology Association and is a member of the European Vasculitis Society (EUVAS), reflecting her standing in the global vasculitis community. She is a regular invited speaker at EULAR, ACR, and the Asia Pacific League of Associations for Rheumatology (APLAR) annual congresses.
Why International Patients Choose Dr. Jiang Lindi
- China's leading vasculitis specialist — Chairwoman of China's national vasculitis committee and EUVAS member
- Avacopan and rituximab expertise — access to the latest vasculitis therapies
- Lupus nephritis authority — comprehensive management including biologic therapy and pregnancy planning
- EULAR and ACR member — aligned with international rheumatology standards
- Antiphospholipid syndrome expertise — particularly relevant for patients with recurrent pregnancy loss or thrombosis
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Zhongshan Hospital, 180 Fenglin Road, Xuhui District, Shanghai
- Appointment Lead Time: 2″4 weeks; urgent cases expedited through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Pre-consultation: Overseas lab results, biopsy reports, and prior treatment records reviewed remotely through CMCS
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking rheumatology care with Dr. Jiang Lindi at Zhongshan Hospital. Our services include priority appointment booking, medical record and lab result translation, remote pre-consultation review, on-site interpretation, accommodation coordination, insurance liaison, and post-treatment follow-up with your home country rheumatologist.
📧 Contact us: contract@medicalsh.com
🌐 medicalsh.com
0 Kommentare